Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by James Investment Research Inc.

James Investment Research Inc. increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 27.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,528 shares of the biopharmaceutical company's stock after acquiring an additional 7,949 shares during the quarter. James Investment Research Inc.'s holdings in Halozyme Therapeutics were worth $2,331,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. Avantax Advisory Services Inc. grew its position in Halozyme Therapeutics by 23.2% in the 4th quarter. Avantax Advisory Services Inc. now owns 9,766 shares of the biopharmaceutical company's stock valued at $467,000 after buying an additional 1,839 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Halozyme Therapeutics in the 4th quarter valued at $1,958,000. Royce & Associates LP grew its position in Halozyme Therapeutics by 58.9% in the 4th quarter. Royce & Associates LP now owns 196,999 shares of the biopharmaceutical company's stock valued at $9,419,000 after buying an additional 72,988 shares during the last quarter. Cibc World Markets Corp purchased a new position in Halozyme Therapeutics in the 4th quarter valued at $558,000. Finally, South Street Advisors LLC grew its position in Halozyme Therapeutics by 34.0% in the 4th quarter. South Street Advisors LLC now owns 229,765 shares of the biopharmaceutical company's stock valued at $10,985,000 after buying an additional 58,350 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Jeffrey William Henderson sold 4,497 shares of the company's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the transaction, the director owned 28,611 shares of the company's stock, valued at $1,727,246.07. This represents a 13.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at approximately $41,403,763.17. This represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 64,497 shares of company stock valued at $3,533,884 in the last three months. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO traded down $0.94 during midday trading on Friday, hitting $56.88. 337,258 shares of the stock were exchanged, compared to its average volume of 1,746,313. The company has a 50 day moving average price of $54.48 and a 200-day moving average price of $57.15. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51. The stock has a market cap of $7.01 billion, a P/E ratio of 15.14, a PEG ratio of 0.39 and a beta of 1.15. The company has a current ratio of 8.39, a quick ratio of 7.30 and a debt-to-equity ratio of 3.13.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The firm had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. During the same quarter in the previous year, the company posted $0.79 EPS. The firm's revenue for the quarter was up 35.2% on a year-over-year basis. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analyst Ratings Changes

HALO has been the topic of a number of analyst reports. The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. Wells Fargo & Company boosted their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $73.00 to $62.00 in a research report on Wednesday, May 14th. Finally, Benchmark downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $62.70.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.